OpenAI Launches GPT-Rosalind, A Restricted AI Model Built For Life Sciences That Outperforms 95% Of Human Experts
Summary
OpenAI launches GPT-Rosalind, a restricted life sciences AI model that outperforms 95% of human experts in RNA sequence prediction and surpasses other AI on science benchmarks, with access limited to approved organizations like Amgen and Moderna due to misuse concerns.
Key Points
- OpenAI launches GPT-Rosalind, a frontier reasoning model purpose-built for life sciences, offering expert-level knowledge in genomics, chemistry, protein engineering, drug discovery, and translational medicine.
- GPT-Rosalind outperforms other AI models on science benchmarks and surpasses 95% of human experts in RNA sequence prediction, while a companion Life Sciences research plugin connects researchers to over 50 scientific databases and tools.
- Access to GPT-Rosalind is restricted to approved organizations like Amgen, Moderna, and the Allen Institute due to misuse risks, signaling a broader industry shift toward powerful, domain-specific AI models that are not made publicly available.